Read all posts

Dead Ends in Alzheimer’s Research Expose Need for New Drug Studies.

A review of existing research for pharmacological answers to Alzheimer's disease (AD) catalogs a litany of failures and calls for an aggressive re-dedication to increase the AD drug development pipeline. The first of its kind research study is published in the journal Alzheimer's Research & Therapy.

Read the article on Psychcentral

Dr. Sears Comments:

Dr. Barry Sears

Maybe there is just a need for some common sense. If Alzheimer’s is an inflammatory disease, doesn’t it make sense taking high doses of anti-inflammatory omega-3 fatty acids that can get into the brain should be the primary treatment?

Leave a Reply

Your email address will not be published. Required fields are marked *